title: Prope tolerance: is it the end or the means?
authors.forename: Paul E
authors.initials: PE
authors.lastname: Morrissey
mesh_terms: D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D002648:Child; D006084:Graft Rejection / Q000517:prevention & control; D006085:Graft Survival / Q000276:immunology; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D011300:Preoperative Care; D015996:Survival Rate; D017741:Survivors; D016559:Tacrolimus / Q000627:therapeutic use*; D018183:Transplantation Chimera / Q000276:immunology; D023001:Transplantation Tolerance / Q000187:drug effects / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab; D016559:Tacrolimus